- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Kytopen Announces Automated Gene Editing Platform
The platform will accelerate cell therapy discovery, development, and manufacturing.
Kytopen, a biotechnology company specializing in high-throughput cellular and genome engineering platforms, announced the initiation of an early access program for the Flowfect Discover™, an innovative gene delivery platform to engineer cells with unparalleled precision and efficiency. Strategically positioned at industry-leading Contract Development and Manufacturing Organizations (CDMOs) and Translational Academic Medical Centers, Flowfect Discover™ enables the swift and streamlined delivery of complex genetic engineering materials, such as CRISPR, mRNA, and DNA, to up to 96 samples in minutes.
"We are thrilled to unveil the Flowfect Discover™ platform, which represents a significant leap forward in our pursuit of advancing gene modified cellular therapies. By working closely with our collaborators and sharing future developments, we hope to increase patient access to these promising living medicines," states Paulo Garcia, CEO & Co-Founder of Kytopen. "Our company aims to empower researchers and developers by enabling more cost-effective innovation that solves manufacturing challenges at the discovery stage of cellular therapies. The introduction of the Flowfect Discover™ platform at earlier development phase will result in reduced development cost and time savings, contributing to improved patient impact."
Continue reading this story here.
